Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 4;15(9):6994-7003.
doi: 10.1039/d5ra00488h. eCollection 2025 Feb 26.

Discovery of novel theophylline derivatives bearing tetrazole scaffold for the treatment of Alzheimer's disease

Affiliations

Discovery of novel theophylline derivatives bearing tetrazole scaffold for the treatment of Alzheimer's disease

Nguyen Viet Hung et al. RSC Adv. .

Abstract

Alzheimer's disease (AD) is associated with AChE and BACE1 enzymes. Designing inhibitors for preventing these enzymes can be benefit for AD treatment. In this context, theophylline derivatives were generated to prevent the biological activity of AChE and BACE1. In particular, the potential inhibitory of these compounds was rapidly and accurately estimated via knowledge-methods. The in vitro tests were then performed to validate the artificial intelligent approach. Among these, compound 12 exhibited the most potent AChE inhibition with an IC50 of 15.68 μM, while showing limited activity against BACE1. In addition, six compounds were indicated that are able to inhibit AChE, however, the theophylline derivatives play poor performance over the BACE1 target. Atomistic simulations were finally applied to clarify the ligand-binding mechanism to the biological target. The outcomes disclose that theophylline derivatives rigidly form van der Waals interactions to AChE via π-stacking and SC contacts. Overall, the theophylline derivatives may offer a potential scaffold for novel anti-AD agents.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts to declare.

Figures

Fig. 1
Fig. 1. (A) Structure of theophylline compound as an AChE inhibitor; (B) structure of tetrazol compound as an AChE inhibitor; (C) design targeted compounds.
Scheme 1
Scheme 1. General procedure for synthesis final compounds 11–27. Reagents and conditions: (a) ClCH2CN, K2CO3, KI, acetone, 60 °C, 4 h; (b) (i) NaN3, ZnCl2, DMSO, 120 °C, 2 h; (ii) halogenide-ester derivatives, DMSO, 90 °C, 12 h; (c) (i) NaOH, MeOH, rt, 2 h; (ii) HCl to pH = 2–3; (d) aniline/phenol derivatives, EDC·HCl, DMAP, HOBt, DCM, DMF, rt to 50 °C, 12 h.
Fig. 2
Fig. 2. FELs of six complexes AChE + compounds over equilibrium conformations via PCA approach during interval 100–200 ns of MD simulations. In particular, (A–F) patterns are FEL of compounds 12, 15, 18, 22, 25, and 26, respectively.
Fig. 3
Fig. 3. Two-dimension ligand-binding poses of AChE – theophylline derivatives matching to the minima a, a′, b, c, c′, d, d′, e and f. The diagram were generated via the Maestro free version.

Similar articles

References

    1. Alzheimer's Association Report: 2024 Alzheimer's disease facts and figures, Alzheimers Dement., 2024, vol. 20, 5, pp. 3708–3821 - PMC - PubMed
    1. Passeri E. Elkhoury K. Morsink M. Broersen K. Linder M. Tamayol A. Malaplate C. Yen F. T. Arab-Tehrany E. Alzheimer's disease: treatment strategies and their limitations. Int. J. Mol. Sci. 2022;23(22):13954. doi: 10.3390/ijms232213954. - DOI - PMC - PubMed
    1. Chen L.-L. Fan Y.-G. Zhao L.-X. Zhang Q. Wang Z.-Y. The metal ion hypothesis of Alzheimer's disease and the anti-neuroinflammatory effect of metal chelators. Bioorg. Chem. 2023;131:106301. doi: 10.1016/j.bioorg.2022.106301. - DOI - PubMed
    1. Agarwal M. Alam M. R. Haider M. K. Malik M. Z. Kim D. K. Alzheimer’s Disease: An Overview of Major Hypotheses and Therapeutic Options in Nanotechnology. Nanomaterials. 2020;11(1):59. doi: 10.3390/nano11010059. - DOI - PMC - PubMed
    1. Colovic M. B. Krstic D. Z. Lazarevic-Pasti T. D. Bondzic A. M. Vasic V. M. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr. Neuropharmacol. 2013;11(3):315–335. doi: 10.2174/1570159X11311030006. - DOI - PMC - PubMed